Every technology mania eventually meets a loading dock. For global AI infrastructure stocks, that moment has arrived.
The first phase is always the exciting one. Models, chips, demonstrations, conference keynotes delivered in a leather jacket. The second phase is duller and considerably more physical. Someone has to pour the concrete, secure the grid connection, order the switchgear with a lead time measured in quarters, and persuade a utility that this particular substation should be built now rather than in 2031.
Australian investors have just been handed a very clear illustration. Goodman Group reported its FY26 result on 20 August 2026 with a development book of A$19.7 billion, of which 78% is now data centres, and a global power bank of 6.4 gigawatts across 16 cities. Greg Goodman described the constraint plainly: scarcity of power and land is what limits AI and cloud growth, not enthusiasm.
That is the whole thesis, stated by a landlord in Sydney rather than a chief executive in Santa Clara. The money has been committed. The bottleneck is physical. And the listed companies that sit inside the bottleneck are, for the most part, not the ones retail investors have been buying.
The size of the cheque
It is worth pausing on the numbers, because they have moved from large to faintly absurd.
UBS estimates, reported in late August 2026, put total hyperscaler capital expenditure at roughly US$1.009 trillion in 2026, rising to US$1.447 trillion in 2027 and US$1.619 trillion in 2028. Cumulatively that is around US$4.1 trillion across three years, against approximately US$1.292 trillion spent over the previous six years combined. The spending base is not cycling. It is resetting.
The more revealing statistic is the ratio. On the same estimates, Amazon, Alphabet and Microsoft will collectively spend about 102% of their cloud revenue on capital expenditure in 2026, easing to roughly 99% in 2027 and 94% in 2028. These are enormously profitable companies with diversified earnings, so this is not a solvency observation. It is a behavioural one. Every dollar the cloud business earns is being fed straight back into the machine, and then some.
Investors have started to notice. The market’s reaction function has quietly inverted. Raising capital expenditure guidance used to be received as evidence of demand. It is now increasingly received as evidence of cost. Meta learned this the hard way earlier in the year when it lifted full year guidance and was rewarded with a sharp fall.
Which raises the question this article exists to answer. If the spenders are being punished for spending, who is being paid?
Why the bottleneck is where the return lives
The useful distinction is between companies that finance the buildout and companies that monetise it.
Financing it means writing the cheque and hoping the utilisation shows up. A data centre does not generate an attractive return merely because it contains expensive silicon. Capacity has to stay full, customers have to keep paying, and the revenue has to cover depreciation, electricity, financing and operations. That is a genuine risk, and it sits squarely with the hyperscalers.
Monetising it means selling something the buildout cannot proceed without, ideally under a long contract, ideally where supply is constrained by something other than your competitors’ willingness to invest.
That second category is smaller than the marketing suggests. It requires physical assets, long lead times, regulatory permissions or a customer relationship measured in decades. It tends to be unglamorous. It also tends to get paid whether or not the model layer ever produces a profit, which is a rather important property to own in a boom.
Five listed businesses sit inside that category. None of them is cheap. That is addressed at the end, as it should be.
Vertiv Holdings (NYSE: VRT): the equipment
Vertiv sells the unglamorous middle of a data centre. Power trains, uninterruptible supplies, switchgear, thermal management, and the higher voltage direct current architectures now being validated for the next generation of accelerator racks.
The second quarter of 2026 delivered net sales of US$3.274 billion, up 24% on the prior year, adjusted earnings per share of US$1.52, and adjusted operating margin of 22.6%, an improvement of 410 basis points. Management raised full year guidance to approximately US$14 billion of sales at the midpoint with adjusted EPS of US$6.65 to US$6.75.
The margin expansion is the part worth dwelling on. Revenue growth in a boom proves demand exists. Margin expansion alongside it suggests pricing power, which is a rather better indicator of where the shortage actually sits.
The complications are two. European organic growth was only 2% in the quarter, so the story is considerably more American than the headline implies. And the shares closed at US$261.95 on 21 August 2026 for a market capitalisation near US$100.85 billion, having risen over 100% in twelve months and roughly 62% in the calendar year to date, before falling about 13% in the past month. A forward multiple in the low forties and a beta above two is not a quiet holding.
Schneider Electric (EPA: SU): the European incumbent
Schneider spent a century selling circuit breakers and industrial components. It now supplies a substantial share of the electrical backbone of the world’s data centres, from power distribution to cooling to rack systems.
The first half of 2026 produced record revenues of EUR 21.2 billion, up 14% organically, with the second quarter accelerating to 16.5%. Adjusted EBITA reached EUR 4.1 billion at a margin of 19.3%. Management raised full year guidance for organic revenue growth to a range of 10% to 13%, up from 7% to 10%, and lifted the adjusted EBITA growth target to a range of 14% to 19%. Data centres and semiconductors both showed triple digit demand growth in the second quarter.
What makes Schneider interesting is not that it benefits from data centres. Everything on this list does. It is that Schneider is not solely dependent on them. Energy management grew 18% in the quarter and industrial automation grew 11%, with strength across North America, China and India. Grid modernisation is a multi decade requirement that would exist even if artificial intelligence had never been invented, and Schneider sells into it.
The company flagged a currency headwind of EUR 400 million to EUR 500 million for the full year and warned of supply chain disruption from the Middle East affecting the second half. Investors buying European industrials from Australia should also be clear that they are taking a currency position alongside an equity one.
Equinix (NASDAQ: EQIX): the meeting place
If Vertiv and Schneider sell the equipment, Equinix owns the room where the networks meet. Its business is interconnection: the neutral exchange points where clouds, carriers, enterprises and model providers physically connect to each other.
In the second quarter of 2026 Equinix added 9,700 net interconnections, its largest quarterly addition on record, with annualised gross bookings of US$424 million, up 23%. Revenue grew 16% with an adjusted EBITDA margin of 53%. Full year revenue growth guidance was raised to a range of 11% to 12%, and the outlook for 2027 to 2029 now calls for annual revenue growth of 10% to 13% with adjusted EBITDA margin at or above 53% by 2029. Management noted that eight of the top ten model providers and eight of the top ten neocloud operators already run key networking workloads on its platform.
Interconnection is a genuine moat. Its value rises with the number of participants already present, which is a difficult thing for a new entrant to buy.
The complication is capital. Equinix has guided to US$5 billion to US$6 billion of capital expenditure in 2026 and US$5 billion to US$7 billion annually through 2029. That pressures free cash flow, and the shares closed at US$1,065.39 with a market capitalisation near US$105.12 billion, up over 41% in the calendar year, on a forward multiple near 61 and a dividend yield of about 1.8%. A wonderful business at an unforgiving price is still an unforgiving price.
Digital Realty Trust (NYSE: DLR): the shell
Digital Realty is the wholesale landlord. It owns the megawatts that hyperscalers lease years before they intend to switch anything on.
The second quarter produced a record backlog of US$1.9 billion at 100% share and a development pipeline that expanded to 1.4 gigawatts under construction at a total cost of around US$20 billion. Renewals were signed with cash releasing spreads above 25%, which tells you something about the balance of negotiating power in this market. Shortly after quarter end, two further hyperscale leases in the United States added US$410 million of annualised rent at 100% share.
A backlog of that size, at those spreads, is about as close to visibility as this sector offers. The shares closed at US$190.62 with a market capitalisation of US$71.81 billion, an indicated annual dividend of US$4.88 and a yield near 2.5%, having risen close to 25% in the calendar year to date.
The risks are the familiar ones for a real estate investment trust operating at scale. Interest rate sensitivity is real, funding requires regular equity issuance, and reported earnings are noisy because of development timing and asset gains. Investors should read the backlog and the leasing spreads rather than the headline earnings comparison.
Constellation Energy (NASDAQ: CEG): the electrons
The last name is the one that has not worked, which is why it is worth including.
Constellation is the largest owner of nuclear generation in the United States. In the second quarter of 2026 it reported adjusted operating earnings of US$2.55 per share, up from US$1.91 a year earlier, and raised full year guidance to a range of US$11.50 to US$12.50 per share. It signed an additional 920 megawatts of long term power purchase agreements with investment grade customers, running 15 to 20 years and commencing between 2029 and 2032, including a 176 megawatt agreement with Walmart. It cleared regulatory hurdles at the Crane Clean Energy Center, targeting a restart in 2027, and agreed to sell the 606 megawatt Brazos Valley gas plant to LS Power for US$860 million as a condition of its earlier Calpine acquisition.
That is a company signing twenty year contracts to supply the scarcest input in the entire chain. Revenue of US$7.5 billion missed expectations near US$7.94 billion, and the shares have fallen roughly 29% in the calendar year to date, trading around US$261 to US$265.
There is a lesson in that divergence. Owning the bottleneck does not exempt a company from being repriced. Power generators carry regulatory risk, outage risk, integration risk from a very large acquisition, and a valuation premium to utility peers that the market periodically decides it no longer wishes to pay. Investors who assume that a good structural position guarantees a good share price have not been paying attention to Constellation this year.
The common thread across these global AI infrastructure stocks
These five businesses share a set of characteristics that has nothing to do with artificial intelligence and everything to do with why they might endure.
They sell into a constraint rather than a trend. They own assets that take years to replicate: substations, interconnection ecosystems, reactor fleets, manufacturing capacity for high voltage equipment. They contract long, with counterparties that are investment grade. And crucially, they are paid for capacity and connection rather than for the eventual profitability of anyone’s language model.
That last point is the entire argument. The great uncertainty in this cycle is whether artificial intelligence generates enough revenue to justify US$4.1 trillion of spending. That uncertainty falls most heavily on the companies doing the spending. It falls considerably more lightly on the companies collecting a contracted payment for a megawatt, a cross connect or a switchboard.
Risks, and the part where valuations are addressed honestly
They are not cheap. Forward multiples in the forties and sixties, on companies whose growth depends on a capital cycle, is a demanding combination. Buying a good structural position at a poor price has historically been an effective way to earn a mediocre return for several years.
Momentum in this sector is violent in both directions. Vertiv fell roughly 13% in a month while its fundamentals improved. Constellation is down about 29% in the calendar year while signing twenty year contracts. Whatever else these are, they are not defensive holdings.
The capital assumption may not hold. The UBS projections assume spending keeps rising even as the growth rate moderates. That is a forecast, not a fact. If hyperscalers decide the returns are not arriving, order books shorten, and companies built for a US$1.6 trillion annual market will be operating in a smaller one.
The financing layer is getting crowded. Hyperscalers are increasingly funding this buildout with debt, which competes for the same capital as everything else and puts upward pressure on the cost of capital across the market. That is not a neutral development for long duration assets.
Customer concentration is the same in every name. Diversifying across five suppliers to the same handful of buyers is not diversification. It is one position expressed five ways.
Currency and timing. Australian investors take a currency position in every name here. And it is worth noting that Nvidia reports its quarterly result on 26 August 2026, United States time. A single result does not change a structural argument, but it will move sentiment across every stock discussed above, in whichever direction it chooses.
TAMIM Takeaway
The artificial intelligence trade has been priced as a semiconductor story. The physical evidence increasingly says it is a power, land and equipment story, and Goodman’s FY26 result made that point from Sydney with a 6.4 gigawatt power bank and a warning that scarcity of power and land is the binding constraint.
What the market may be underestimating is the durability of demand at the bottleneck compared with the volatility of demand at the application layer. Vertiv, Schneider Electric, Equinix, Digital Realty and Constellation Energy all sell into constraints that take years to relieve, under contracts that are paid regardless of whether the models make money.
What the market is very obviously not underestimating is the price. Every one of these businesses has already re-rated substantially, and one of them has de-rated sharply despite good news, which should be a useful reminder that structural strength and share price direction are separate questions over any period shorter than a decade.
For long term investors, the practical approach is not to chase the theme. It is to build a watch list of businesses that own genuine bottlenecks, understand what each would be worth on more sober assumptions about capital expenditure, and be prepared to act when sentiment inevitably wobbles. The buildout will take a decade. There is no requirement to own all of it this week.
Disclaimer: Constellation Energy (NASDAQ: CEG) is held in TAMIM portfolios as at the date of article publication. Holdings can change substantially at any time.
This week’s reading list is about the distance between a number and the thing that number is supposed to describe. Markets have spent August being reminded that a statutory loss is not a cash outflow, that a record profit can be a price outcome rather than an operating one, and that the measure everyone quotes is rarely the measure that binds. Several of the readings look at what happens when investors mistake conviction for accuracy, or a backtest for a live position. Others examine the same problem in physical form: a data centre lease that runs four years against debt that runs to 2049, a racehorse bred so precisely for speed that the breed lost the diversity it would need to keep improving, an ice business that looks like a commodity until you notice that nobody can ship it more than a few hundred kilometres. There is also a piece on how quickly the economics of the open web have been rewritten beneath everyone’s feet, and one on where subjective experience might actually sit in the brain, because not every good question has a ticker attached. The useful lesson for investors is that the answer to one question is not the answer to all of them, and a locally successful outcome is not a complete one. The best investors are not trying to predict every headline. They are trying to work out which clock is running, and which one runs out first.
📚 The Situational Awareness Fund Blow-up: Collateral Damage from Investment Conviction: Aswath Damodaran’s post-mortem on the Aschenbrenner implosion, and the best thing written on the episode. He is less interested in the AI thesis than in what conviction actually is, where it comes from, and why it so reliably ends in position sizes and leverage that the underlying idea cannot support. His three lessons, on leverage truncating your time horizon, on momentum as the uninvited passenger in every strategy, and on humble money beating smart money, are worth the read on their own. (Musings on Markets)
📚 The Clocks on One Building: Four-Year Leases, Sixteen-Year Guarantees, Debt to 2049: Shanaka Anslem Perera reconstructs the financing architecture behind Meta’s AI data centre ventures from the public filings, and finds not one duration but several running side by side. A four-year initial lease, options out to twenty years, a residual value guarantee declining over sixteen, and amortising notes maturing in 2049. The point is not that something is wrong. It is that credit recovery, accounting control, physical succession and workload continuity are four different outcomes, and success on one is routinely reported as success on all of them. Long, but the most useful thing we have read on AI infrastructure risk. (Shanaka Anslem Perera)
📚 How Hard Can Quant Trading Really Be? I Tried It to Find Out: Lauren Leek, a political economy PhD with Python and free data, builds three quant strategies on a laptop and reports the results honestly, including the machine learning model that looks spectacular until you ask about beta, drawdowns and execution assumptions. Her conclusion is the right one: the professionals’ edge is not foresight, it is data, infrastructure and the discipline to build systems that do not break when conditions change. The comment from Dan Davies underneath is almost worth the price of admission by itself. (Lauren’s data Substack)
📚 How Trump’s Next Tariffs Could Drive Companies Back to China: Chad Bown at the Peterson Institute traces what actually happened to smartphone and clothing supply chains under the 2025 tariffs, and finds that what mattered was never the level of the tariff but the differential between countries. The looming irony is that the next round, paired with lower rates on nonsensitive Chinese goods, could push sourcing back toward exactly the place the policy was designed to move it away from. A clean example of second order effects doing the opposite of what the first order intended. (Peterson Institute)
📚 The Ultimate Horse: Sophie Fessl on the thoroughbred paradox. Breeders have spent three centuries selecting for speed, and race times have not meaningfully improved since about 1910. Roughly 95 per cent of living thoroughbreds descend from a single eighteenth century stallion, ten heavily crossed ancestors account for more than 80 per cent of inbreeding in the Australian thoroughbred population, and the inbreeding itself correlates with shorter and less lucrative careers. Optimise hard enough for one variable and you eventually breed away the diversity that would let you keep improving. Portfolio managers may find that uncomfortably familiar. (Works in Progress)
📚 Inside the Billion-Dollar Industry That’s Keeping Your Beer Cold: Lauren Larson on Reddy Ice, packaged ice and one of the more instructive business models you will read about this year. Ice cannot be shipped economically beyond a certain radius and must be kept cold on arrival, which means the industry stays stubbornly local no matter how large the operator gets. The chief financial officer’s line, that the business is not recession proof but recession resistant, is a better summary of defensive earnings than most sell side notes manage. Note also the roll-up strategy, the consolidation of a competitor this year, and what ice sales reveal about when people are and are not gathering. (Texas Monthly)
📚 What Was the Internet? Five writers on how quickly the economics of the open web have been rewritten as AI answers replace links. Siva Vaidhyanathan’s contribution has the numbers that matter for anyone modelling a media, marketplace or search dependent business: click-through on top ranking pages down sharply where AI summaries appear, and zero-click rates across search now estimated at roughly 60 to 68 per cent of queries. Whatever your view of the essays’ politics, the structural change they describe is a real revenue event for a lot of listed companies. (Boston Review)
📚 The Tantalizing Possibility of Locating Consciousness in the Brain: Daniel Freeman, an MIT scientist, on what artificial intelligence has done to a long-standing assumption in neuroscience. If machines can now reason, plan and joke without anything resembling a biological neuron, then perhaps cognition and consciousness were never the same problem, and subjective experience may sit in far older and more anatomically discrete structures deep in the brain. No investment application whatsoever. We include it anyway. (NOEMA)
For most of the past twenty years, owning BHP Group Limited (ASX: BHP) meant owning iron ore. Everything else was a portfolio garnish. Investors could argue about copper, coal, oil or potash, but the cash came out of the Pilbara and everyone knew it.
That is no longer true. In the FY26 result handed down on 18 August, copper generated more than US$18 billion of underlying EBITDA, or 54 per cent of the group total. Copper is now the biggest earnings driver at BHP, and it happened faster than most investors were positioned for.
The same result also contained a US$2.3 billion impairment on the Jansen potash project, a 41 per cent cost increase on its second stage and a forward copper production guide that steps down meaningfully. BHP is a better business than it was three years ago and a more complicated one. Both things can be true.
The numbers
Revenue rose 15 per cent to US$58.76 billion. Attributable profit rose 9 per cent to US$9.83 billion. Underlying attributable profit, which strips out the Jansen write-down and other one-off items, rose 30 per cent to US$13.20 billion from US$10.16 billion. Underlying EBITDA climbed to US$32.95 billion from US$25.98 billion. Underlying basic earnings per share reached 260.0 US cents against 200.2 US cents in the prior year.
The dividend was the headline for income investors. BHP declared a fully franked final dividend of US99 cents per share, well up on the US60 cents paid a year earlier, taking the FY26 total to US$1.72 per share. That is the highest full year payout in four years and represents a payout ratio of 72 per cent, comfortably above the 50 per cent minimum under the capital allocation framework. Total cash returns announced for FY26 came to US$8.7 billion.
The balance sheet did the quiet work. Net debt closed at US$8.7 billion, down from US$12.9 billion a year earlier and better than the roughly US$11 billion management had guided to. A miner that reduces debt by more than US$4 billion while lifting its dividend and spending heavily on growth is generating a great deal of cash.
The shares rose about 2.7 per cent on the day to around A$63.87, within reach of the record high of A$65.98 set in mid June.
Where the money came from
Price did more work than volume.
The average realised copper price rose 35 per cent to US$5.74 per pound. Iron ore realised US$84.56 per wet metric tonne, up 3 per cent. Steelmaking coal averaged US$210.21 per tonne, up 8 per cent, while energy coal slipped 3 per cent to US$104.28 per tonne.
Volumes were more mixed. Iron ore production hit a record 265 million tonnes, up 1 per cent, with Western Australia Iron Ore contributing 257 million tonnes. Copper production actually fell 3 per cent to 1,953 thousand tonnes, held back by a 21 per cent decline at Pampa Norte. In other words, copper became the dominant earnings contributor despite producing less of it, which tells you how much of the FY26 result is a price outcome rather than an operating one.
Costs held up. Unit costs came in at the bottom end of guidance across the copper assets, within guidance at Western Australia Iron Ore and towards the top end at BMA. Delivering cost guidance through an inflationary period is genuine execution and should not be waved past.
The pivot is real, and it is expensive
BHP is explicitly building itself into a copper company with an iron ore cash machine attached. Management expects organic growth projects to support attributable copper equivalent production growth of approximately 3 to 4 per cent annually between FY27 and FY35.
Getting there costs money. FY27 capital and exploration expenditure is guided at approximately US$11 billion, split between US$1.0 billion of deferred stripping, US$3.2 billion of baseline sustaining capital, US$2.7 billion of non-recurring sustaining capital, US$3.8 billion of growth capital and US$0.3 billion of exploration. Over the medium term the allocation runs at roughly US$5.4 billion to copper, US$3.1 billion to iron ore, US$2.0 billion to potash and US$0.5 billion to coal.
The individual projects are substantial. At Escondida, US$0.5 billion of pre-commitment funding has been approved for a new concentrator ahead of a possible final investment decision in calendar 2027 or 2028. In the Pilbara, the Ministers North project at roughly US$0.9 billion is intended to add about 20 million tonnes per annum with first ore in FY29, sustaining Western Australia Iron Ore above 305 million tonnes per annum. In Argentina, the Vicuña copper district secured 40 years of tax and regulatory certainty under the government’s investment incentive regime. BHP has also applied to restart the mothballed Cerro Colorado mine in Chile and agreed transactions lifting its stake in Faraday Copper to about 32.5 per cent.
This is a serious, coherent growth pipeline. It is also a commitment of roughly US$11 billion a year, every year, before a dollar reaches shareholders.
Jansen is the cautionary tale, and it deserves a full hearing
The Jansen potash project in Saskatchewan was approved in August 2021 with a Stage 1 investment estimate of US$5.7 billion. That estimate moved to a range of US$7.0 billion to US$7.4 billion in July 2025 and has now been updated to approximately US$8.4 billion including contingencies. Stage 1 is 84 per cent complete and first production remains scheduled for mid calendar 2027.
Stage 2 has been worse. Following a detailed review completed in June 2026, the total investment estimate rose from US$4.9 billion to US$6.9 billion, a 41 per cent increase, with first production pushed to late FY2031. Stage 2 is 16 per cent complete. At consensus potash prices, the internal rate of return on Stage 2 is 11 per cent with an eight year payback.
Given the higher forecast capital intensity across the project, BHP recognised a US$2.3 billion impairment in FY26 against its investment to date. Barclays has calculated total cash deployment across Jansen at roughly US$20.3 billion, of which about US$4.1 billion has now been impaired, including a US$1.8 billion post-tax write-down back in FY21.
Combined, the two stages are expected to produce 8.5 million tonnes per annum, around 10 per cent of global potash supply, from an asset BHP expects to operate for more than 60 years at the low end of the cost curve.
That may still prove to be a good asset. An 11 per cent return on a multi decade, low cost position in a commodity with reasonable demand fundamentals is not a disaster. But it is a long way from the returns that justified the original decision, and the pattern matters more than the number. Large greenfield mining projects have a persistent tendency to cost more and take longer than approved. Investors should read BHP’s future growth commitments with that history in mind, not because management is careless, but because the industry is.
Risks and counterpoints
Copper volumes step down before they step up. FY27 copper guidance is 1,650 to 1,800 thousand tonnes, more than 150 thousand tonnes below FY26 actual output, driven by grade decline at Escondida. Grade decline is a structural feature of ageing orebodies, not a cyclical dip. The new concentrator is the answer, but it is years away and not yet approved.
The result is heavily price dependent. With copper at 54 per cent of underlying EBITDA and the realised price up 35 per cent, the sensitivity is significant. As a rough guide, a 10 per cent move in the realised copper price at FY26 volumes is worth in the order of US$2 billion at the EBITDA line before any cost offsets. That works powerfully in both directions, and FY26 caught the favourable side.
The payout ratio is a cycle outcome, not a promise. A 72 per cent payout at the top of a strong copper year is not a forward commitment. BHP’s dividend is set by applying a payout ratio to underlying profit, which means the payment falls when the commodity falls. Income investors treating US$1.72 per share as a base case should be careful.
Capital intensity constrains flexibility. Roughly US$11 billion of annual capex against a dividend of this size leaves less room than the headline cash returns suggest, particularly if prices soften.
Leadership and execution. Brandon Craig has taken over as chief executive. New management at a large miner usually brings a portfolio review, and reviews can produce impairments, disposals or changed capital priorities.
Currency and franking. Dividends are declared in US dollars, so the Australian dollar amount received varies with the exchange rate. They are, however, fully franked, which remains genuinely valuable for SMSF and low tax rate investors and is a meaningful part of the total return story on this stock.
Investor implications
The reason BHP is worth thinking about carefully right now is not the FY26 result. It is the starting price.
The shares have roughly doubled from the April 2025 low of A$33.25 and sit close to their record high. Part of that reflects genuine improvement in the business, particularly the copper mix shift and the balance sheet. Part of it reflects a rotation out of expensive banks into materials that began in late 2025 and has run hard.
For long term investors, the practical question is whether you are buying a structurally better portfolio or a cyclically flattered one. The honest answer is both, in proportions that depend on where you think the copper price goes. BHP’s own case rests on electrification, grid investment and data centre driven demand, which is a reasonable thesis and also a widely held one.
What can be said with more confidence is that BHP now converts cash better, carries less debt and owns a growth pipeline weighted towards the commodity with the strongest structural demand argument. What can be said with less confidence is what anyone should pay for that.
TAMIM Takeaway
BHP delivered a strong FY26. Underlying profit rose 30 per cent to US$13.2 billion, net debt fell to US$8.7 billion, and the fully franked dividend reached US$1.72 per share, the highest in four years. Copper overtook iron ore as the largest earnings contributor, generating more than half of group underlying EBITDA.
What the market may be underweighting is how much of that came from a 35 per cent lift in the realised copper price rather than from volume growth, and how much capital the next decade of growth requires. FY27 copper volumes step down on Escondida grades, capex runs at around US$11 billion a year, and the US$2.3 billion Jansen impairment is a live demonstration that large mining projects rarely land on their original budget.
For long term investors, the lesson is not to avoid cyclical businesses. It is to be clear about which part of a strong result is the business and which part is the commodity. BHP’s iron ore and copper assets are genuinely world class and the capital allocation framework has served shareholders well. The share price, close to a record high after roughly doubling from its 2025 low, has already absorbed a good deal of that.
The mindset to bring is the one that suits resources generally: focus on cost position, balance sheet strength and payout discipline, accept that the earnings will swing, and be more interested in what you pay than in what the last twelve months delivered.
Disclaimer:BHP Group Limited (ASX: BHP) is held in TAMIM portfolios as at the date of article publication. Holdings can change substantially at any time.
Large cap investing produces very few moments where the reported number and the share price move in opposite directions with such conviction. On 18 August, CSL Limited (ASX: CSL) reported a statutory net loss after tax of US$2.6 billion, the worst headline result in the company’s listed history. The shares closed the day up roughly 17 per cent.
For anyone who learned that profits drive share prices, this looks like the market losing its mind. It is closer to the opposite. The market spent FY26 pricing CSL for continued deterioration, and this result was the first credible evidence in two years that the core business has stopped going backwards. The loss was accounting. The guidance was cash.
That distinction is the whole article.
How CSL got here
CSL is three businesses. CSL Behring collects human plasma and turns it into therapies, principally immunoglobulin, along with haemophilia products and albumin. CSL Seqirus makes seasonal influenza vaccines. CSL Vifor, acquired in 2022, sells iron deficiency and dialysis related products.
For most of the past two decades, Behring was one of the highest quality franchises on the ASX. Plasma collection is capital intensive, heavily regulated and genuinely difficult to replicate at scale, which is precisely why investors were willing to pay a premium multiple for a very long time.
That premium unwound with unusual violence. CSL fell roughly 52 per cent across FY26, making it one of the worst performers in the S&P/ASX 200. The reset began in August 2025 with a workforce reduction of up to 15 per cent and a planned demerger of the influenza vaccine business. A second downgrade arrived in October when weak vaccination rates forced another rethink. Two resets in as many quarters did more damage to management’s forecasting credibility than to the underlying franchise. Most of the remaining damage was done on 11 May, when an interim chief executive review cut FY26 guidance again.
By early June the shares had found a floor. They then rallied 49.5 per cent from the 3 June low into the result, which is worth holding in mind. A large part of the recovery had already happened before 18 August.
What the result actually said
Revenue was US$15.8 billion, down 1 per cent at constant currency. Underlying NPATA was US$3.1 billion, down 2 per cent. Underlying NPAT was US$2.8 billion, down 3 per cent. Gross profit fell 2 per cent to US$8.5 billion and the operating result fell 3 per cent to US$6.8 billion. Cash flow from operations was US$3.5 billion.
None of that is growth. All of it landed at or slightly ahead of a market that had been repeatedly disappointed.
The statutory loss came from two places. CSL booked US$7.1 billion of pre-tax impairments across FY26, of which US$5.5 billion landed in the second half, and incurred US$799 million of restructuring costs. The impairments reflect adverse changes to commercial outlooks, the arrival of generic competition, regulatory developments and revised site utilisation assumptions.
By division, Behring revenue fell 1 per cent to US$11.4 billion. Immunoglobulin revenue was broadly flat at about US$6.25 billion, held back by Medicare Part D and channel inventory normalisation, but second half revenue grew 7 per cent year on year and RBC pointed to second half immunoglobulin growth of 14 per cent on its measure. Haemophilia fell 1 per cent to US$1.5 billion, with HEMGENIX revenue up 25 per cent. Albumin dropped 17 per cent to US$1.1 billion on Chinese government cost containment. Vifor rose 3 per cent to US$2.4 billion. Seqirus fell 8 per cent to US$2.0 billion, though seasonal influenza revenue itself rose 4 per cent to US$1.6 billion, with the decline explained by non-recurring avian flu revenue in the prior year.
Why the market bought it
Three things.
First, the FY27 guidance beat. CSL expects group revenue broadly in line with FY26 at constant currency, but underlying NPAT growth of approximately 5 per cent excluding restructuring and impairment items, against consensus of 2 per cent. That implies NPAT of roughly US$2.98 billion versus consensus of US$2.83 billion. Behring is guided to mid single digit revenue growth, Seqirus to low single digit growth, and Vifor down approximately 25 per cent on iron generics.
Second, the second half immunoglobulin performance. Behring is the reason to own CSL. If immunoglobulin demand is reaccelerating and plasma collection economics are improving, the rest is detail. RBC described the result as a beat across revenue, EBITDA and NPATA, with every segment exceeding revenue and gross profit expectations.
Third, the capital return. CSL announced a new US$1.1 billion buyback and declared a final dividend of US$1.62 per share, taking the full year to US$2.92. A company that genuinely believed it was impaired does not simultaneously commit to buying back its own stock.
Interim chief executive Gordon Naylor described FY26 as a year of reset with a clear path back to sustainable growth. Management is entitled to say that. Investors are entitled to check it in twelve months.
What a US$7.1 billion impairment does and does not tell you
This is the part worth explaining plainly, because it recurs across the market every reporting season.
An impairment is an accounting adjustment to the carrying value of an asset on the balance sheet. It is non-cash. It does not touch the operating cash flow the business generated this year, and it does not change the cash the business will generate next year. What it does tell you is that the price previously paid for something, or the future assumed for it, is no longer supportable.
So the impairment is backward looking and the guidance is forward looking, and the market was buying the second.
But it would be dishonest to treat the write-down as meaningless. US$7.1 billion of impairment is a formal admission that capital was destroyed. A meaningful part of that traces to Vifor, an acquisition that has not delivered and is now guided to decline 25 per cent in FY27. Shareholders paid real money for those assets. Writing them down clears the runway for the reported numbers to look better from here, which is convenient, and it is exactly why underlying and statutory results should both be read rather than one being discarded.
The risks that did not go away on 18 August
CSL still has no permanent chief executive. The global search has been running since February. A business attempting a multi year transformation with an interim leader carries an obvious strategic risk, and the eventual appointment could bring another change in emphasis.
The Seqirus demerger, originally planned for completion by the end of FY26, was deferred in October 2025 and still has no confirmed completion date. That is unresolved value, and unresolved value can move in either direction.
Vifor is guided to fall approximately 25 per cent in FY27 as iron generics arrive. That is a known headwind, but known headwinds have a habit of being deeper than modelled.
Seqirus faces softer United States immunisation rates, which management expects to decline more slowly than in recent seasons rather than to recover.
The transformation program targets US$500 million to US$550 million in annual savings by FY28, against roughly US$176 million delivered in FY26. Cost savings are real, but a business the market once valued on growth cannot be repriced upward on cost savings alone.
Sentiment is not unanimous. Macquarie entered reporting season with CSL as its least preferred healthcare name and indicated the result did not change that view.
Finally, the guidance is stated at FY26 exchange rates, and the dividend is declared in United States dollars and is largely unfranked. For Australian income investors, particularly SMSF retirees accustomed to fully franked yield, that matters more than the headline payout suggests.
Valuation, honestly
Before the result, the average analyst price target sat at about A$137.84, with the most bullish at A$196.48 and UBS carrying a buy rating and a A$158 target. The stock traded around A$157 to A$159 on the day of the result. Those targets are pre-result and will be revised upward by some brokers and left alone by others, so treating them as a valuation anchor right now would be a mistake.
The more useful question is what multiple a business growing underlying profit at roughly 5 per cent deserves. CSL spent a decade priced as a compounder. It is currently guiding to something closer to a recovering industrial with a very good core franchise attached. Those two descriptions carry very different multiples, and the gap between them is where the argument sits.
What long term investors should take from this
The lesson generalises well beyond CSL.
First, separate accounting events from cash events. A statutory loss driven by impairment tells you about the past. Guidance, cash flow and capital returns tell you about the next twelve months. Both matter, but they answer different questions.
Second, be careful with quality narratives that have already been repriced. CSL was not a bad business in FY26. It was an expensive business meeting a period of genuine operational difficulty, and the de-rating was more about the starting multiple than the ending one.
Third, note how much of the move happened before the news. The stock rose 49.5 per cent from its June low before it reported. By the time a turnaround is obvious in the numbers, a good deal of it is usually in the price.
TAMIM Takeaway
CSL reported a US$2.6 billion statutory loss and the shares rose 17 per cent, because the market was pricing further deterioration and instead received an FY27 guidance beat, evidence of a second half recovery in immunoglobulin and a US$1.1 billion buyback. The US$7.1 billion of impairments is non-cash and backward looking, but it is also a formal acknowledgement that capital was destroyed, most visibly in Vifor.
What the market may be missing is that the recovery case now depends on execution rather than valuation. The easy repricing has happened. From here, CSL has to actually deliver mid single digit Behring growth, appoint a permanent chief executive, resolve the Seqirus demerger and absorb a 25 per cent decline in Vifor.
For long term investors, the practical question is not whether the worst is behind CSL. It is whether a business guiding to roughly 5 per cent underlying profit growth should be valued the way a compounder was valued, or the way a recovering industrial is valued. That question is not answered by one result, and it will not be answered by one year.
The mindset to bring is patience with the business and scepticism toward the narrative. Turnarounds are usually slower and less linear than the first good day suggests.
This week’s list is not about markets. It is about the gap between the explanation you are handed and the machinery that is actually running underneath it. Most of us handle that gap badly, because the offered explanation is almost always tidier, and tidy feels true. What follows comes at the problem from six directions: an evolutionary puzzle about your own hands, a privacy investigation into what you pay for groceries, an essayist watching an industry quietly lose faith in itself, a professional wrestler who broke the story on purpose, a restaurateur finally admitting what went wrong, and a drilling rig that turned up in Greenland before anyone said yes. None of it will help you pick a stock next week, which is very much the point. The habit of asking who is telling you this, and what they gain from you believing it, is worth more over thirty years than any single idea.
Roughly nine in ten humans favour their right hand, and no other primate does anything of the sort. The explanation, it turns out, may have nothing to do with hands at all, and rather a lot to do with legs and the long business of learning to walk upright. A short, satisfying read about how the most obvious fact about your own body can have a cause you would never have guessed. Useful calibration for anyone who thinks the intuitive explanation is usually the right one.
The same shopping cart can cost two people two different amounts, and the difference is not a coupon. Mozilla’s researchers dig into surveillance pricing, the data brokers who decide who is likely to pay more, and the entirely legal machinery that makes it possible. This is a piece about the quiet end of the single posted price, an idea so old we had stopped noticing it was an idea. Worth reading if only to make you look twice at the next fare, quote or checkout total.
The essay opens with a man on a commuter train talking about EBITDA and margin expansion for half an hour, then pulling out knitting needles and lighting up while describing the hat he is making for his niece. Horwath uses that image to explore what happens when a well paid, well educated class of workers stops believing its work matters, and what artificial intelligence has to do with the timing. It is sharp about the difference between appearing productive and being useful, and honest enough to acknowledge that not everyone will feel sympathy. Read it as an essay about meaning at work, or read it as a note on where a very large pool of human capital may be heading.
Yes, professional wrestling. Stay with it. In 1996 the most bankable good guy in the business turned villain, and Shoemaker argues the move did not merely rewrite one man’s legacy, it permanently changed what audiences expect from a story. Once the crowd learns the narrative can invert, it never quite trusts a straight one again. A genuinely interesting piece on narrative, expectation and the moment a rule everyone assumed was fixed turns out to be a choice.
Twenty years after Setting the Table became required reading for anyone in hospitality, Danny Meyer has written the other book: the one about the closures, the failed juice venture, the fine dining restaurant on the eighteenth floor of a hospital, and the no tipping policy that quietly disappeared. The admission that stings most is that he waited two years too long to shut Tabla. Rodbard’s review is warm but clear eyed about why this matters more than another success memoir. One of the commenters puts it better than we could: nobody wants to write down a position they defended in public, and admitting it late costs everything.
Equipment came ashore for exploratory drilling. Greenland’s government then pointed out that it had granted no approval for any of it. A short news piece that is really about something larger: how resource claims in the Arctic are increasingly being settled by whoever moves first, with the paperwork invited to catch up afterwards. File under things that will matter more in five years than they appear to today.
Vertiv sells the unglamorous middle of a data centre. Power trains, uninterruptible supplies, switchgear, thermal management, and the higher voltage direct current architectures now being validated for the next generation of accelerator racks.
Schneider spent a century selling circuit breakers and industrial components. It now supplies a substantial share of the electrical backbone of the world’s data centres, from power distribution to cooling to rack systems.
If Vertiv and Schneider sell the equipment, Equinix owns the room where the networks meet. Its business is interconnection: the neutral exchange points where clouds, carriers, enterprises and model providers physically connect to each other.
Digital Realty is the wholesale landlord. It owns the megawatts that hyperscalers lease years before they intend to switch anything on.
The last name is the one that has not worked, which is why it is worth including.
